Long-Term Safety, Efficacy and Pharmacokinetics of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) Monoclonal Antibody SHP647 in Crohnʼs Disease: The OPERA II Study
Geert D’Haens(Amsterdam University Medical Centers), William J. Sandborn(University of San Diego), Walter Reinisch(Medical University of Vienna), Dino Tarabar(Military Medical Academy), Fabio Cataldi(Pfizer (United States)), Dong Il Park(Kangbuk Samsung Hospital), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Satyaprakash Nayak(Pfizer (United States)), Édouard Louis(Centre Hospitalier Universitaire de Liège), Scott D. Lee(University of Washington), Anindita Banerjee(Pfizer (United States)), Xavier Hébuterne, Steven W. Martin(Mississippi Delta Community College), Kenneth J. Gorelick, Jochen Klaus(University Hospital Ulm), Maria Kłopocka(Nicolaus Copernicus University)
Cited by 0
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Crohn's disease
|The Lancet|2012|2.1k
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k